Knight Therapeutics Inc commercializes Trelstar® in Canada

Following the exclusive agreement between Debiopharm and Knight announced in January 2020, Knight has taken over activities from Allergan, our previous partner, for the commercialization of Trelstar® in Canada.

Trelstar® (triptorelin) is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. First registered in France in 1986, triptorelin is currently marketed in more than 80 countries and is market leader in many territories worldwide. In Canada, triptorelin is registered for Prostate Cancer as Trelstar® and was first approved in 1999 for the palliative treatment of hormone dependent advanced carcinoma of the prostate gland and the management and relief of chronic pain associated with endometriosis.

Access Knight’s full press release here.